2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

2013 Symposium Photos

2012 Featured Talks

2012 Symposium Photos

2011 Featured Talks

2011 Symposium Photos

Past Symposia in the Press

2013 Featured Talks » Panel Discussion: Funding translation -- novel partnership models and creative sources of capital

Part One

Part Two

Part Three

Part Four

Part Five

Panel Discussion:
Funding translation -- novel partnership models and creative sources of capital

The panel will discuss how to measure the success of innovative partnering models and novel ways to access dollars.

Steven Edelson, SciBX:Science-Business eXchange, BioCentury Publications

Panel Members:
Elona Baum, California Institute for Regenerative Medicine (CIRM)

Ida Deichaite, PhD, Moores Cancer Center

David Kabakoff, PhD, Sofinnova Ventures

Mark Lappe, Inhibrx

Arturo Molina, MD, FACP, Janssen Research & Development

Carl Weissman, Accelerator

Steven Edelson, who serves as Executive Editor of SciBX for BioCentury, has been a writer and editor for BioCentury since 1998, including as Editor of BioCentury Extra and as Senior Writer responsible for financial markets coverage. Steve has a M.S. in biotechnology from Northwestern University, where he also received a B.A. in biochemistry.

Elona Baum, is the General Counsel and Vice President of Business Development for the California Institute for Regenerative Medicine (CIRM). She is an experienced attorney with more than 20 years of practice, mostly in the life sciences and drug development field. As a member of CIRM’s executive team, Ms. Baum is responsible for the strategic initiatives of the agency, as well as overall management of the legal function. Prior to joining CIRM, Ms. Baum held the positions of Associate General Counsel and later Director of Regulatory Policy and Strategy at Genentech, Inc. (1996 to 2009). Prior to Genentech, she practiced law at private firms. Ms. Baum received her BA in Economics from the University of California and her JD from the University of San Francisco School of Law. She served as an extern for Justice John A. Arguelles, California Supreme Court.

Ida Deichaite, PhD, as Director of Industry Relations at UC San Diego Moores Cancer Center, fosters relationships between faculty and industry that result in the translation of faculty’s work into therapies, medical devices and other tools to help patients battling cancer. She also organizes the Cancer Center’s annual Industry/Academia Translational Oncology Symposium, which began in 2004 and has resulted in numerous fruitful collaborations. Previously, Deichaite was Associate Director of Business Development for Avanir Pharmaceuticals, a biotechnology company developing new therapies for CNS indications. During her tenure, she established a technology evaluation program for in-licensing compounds. She also made noteworthy contributions to an early-stage program in inflammation, as well as a late state CNS program.

She is a member of the UCSD Innovation Advisory Board and an editor of the Journal of Translational Medicine. Deichaite is widely published in numerous scientific journals. Deichaite received her Ph.D. in molecular biology from Princeton University.

David Kabakoff, PhD, joined Sofinnova Ventures as an Executive Partner in 2007. David has 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. He currently serves as Chairman of Trius Therapeutics and Chairman of Amplimmune, Inc. He is also a Director of InterMune, Inc.; and Allylix, Inc. Dr. Kabakoff also serves as a Board Observer at Intellikine.

David co-founded Salmedix, Inc., a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, David negotiated the acquisition of Salmedix by Cephalon, Inc. David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros Development Corp. while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.

David received his PhD from Yale University and his B.A. from Case Western Reserve University.

Mark Lappe, has extensive expertise in the biotechnology industry with over twenty years of experience in investment management and building the executive teams of over forty start-up biotechnology and medical device companies. Prior to starting Inhibrx, Mark was the Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in emerging public biotechnology companies. Mark has significant experience in the antibody field through Efficacy’s major investment in Arius Research. Efficacy played the key advisor to Arius and developed the exit strategy that led to the successful sale to Roche in 2008. Additionally, Mark served as a board member of two public biotech companies.

Arturo Molina, MD, FACP, received his M.D. from Stanford University School of Medicine, and continued training at Stanford for Fellowships in Medical Oncology, Biological Sciences and Bone Marrow Transplantation. In 1991, Arturo joined the City of Hope Comprehensive Cancer Center where he was a Faculty Staff Physician and Adjunct Professor. He was on the Board of Directors of the City of Hope Medical Group and President-elect of the City of Hope Medical Staff. In 2002, Arturo joined IDEC as Senior Director, Medical Affairs, ultimately becoming Department Head, Oncology Clinical Development for Biogen-IDEC. In May 2007, Arturo joined Cougar Biotechnology as Senior Vice President, Clinical Research & Development, becoming Chief Medical Officer and Executive Vice-President the following year.

After Cougar Biotechnology was acquired by Johnson & Johnson in July 2009, Arturo continued his leadership of the development of ZYTIGA® (abiraterone acetate), which significantly reduces androgen production by blocking the enzyme cytochrome P450 17 alpha-hydroxylase (CYP17). ZYTIGA® is now approved over 70 countries for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. Most recently, ZYTIGA was approved by the FDA and European Medicines Agency for treatment of men with mCRPC who have not received chemotherapy. Arturo is co-author of numerous publications and presentations concerning the clinical development of ZYTIGA® and its use in mCRPC.

In January 2013, Arturo was appointed Vice President, Oncology Scientific Innovation at the J&J Innovation Center California. Arturo represents the Oncology Therapeutic Area in the highly competitive landscape of external collaborations and partnerships in California and throughout the Western U.S. He will also play a central role in creating and implementing J&J’s external innovation plan to deliver the Oncology TA Strategy. As partnerships are formed, he will lead those collaborations and asset development.

Carl Weissman, serves as the Chairman and CEO of Accelerator. He has been the CEO since its founding in May 2003, and was elevated to Chairman in 2008. Carl is also a past Managing Director at OVP Venture Partners, one of the Accelerator investors and a firm with which he has been affiliated as a Managing Director or previously a Venture Partner since 2006. Prior to Accelerator, from 2001-2006, Carl was a Venture Partner at MPM Capital (Boston) and in that capacity served as President and CEO of Centagenetix, a Cambridge, MA, human genetics company, prior to founding Accelerator on MPM’s behalf. In his role as CEO of Centagenetix, Carl led the February 2003 merger of Centagenetix, with Elixir Pharmaceuticals, and remained on the Board of Directors of the combined entity until January 2005. Prior to joining Centagenetix and MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development.

Carl serves on the Board of the Washington Biotechnology and Biomedical Association (WBBA), the Board of the Oregon Translational Research and Drug Development Institute (OTRADI), and the board of Broadway Bound Children’s Theater in Seattle.